Emerging Company Profile in BioCentury, The Bernstein Report

By | news

OncoSynergy and our lead therapeutic program, OS2966, were featured in an ‘Emerging Company Profile’ in BioCentury, The Bernstein Report on BioBusiness.

See pdf 061614_ECP_OncoSynergy

The Bernstein Report is the flagship weekly publication of BioCentury Publications, Inc. providing analysis and commentary on the biopharma industry.

OS2966 is currently under development for the treatment of orphan cancers with high unmet need. A Phase I clinical trial is being planned for glioblastoma, the most common and malignant brain tumor in adults.

Please contact us at for more information.

OncoSynergy and CMC Biologics Enter into Agreement for OS2966 Drug Program

By | news

OncoSynergy and CMC Biologics enter into agreement to develop and manufacture material for IND enabling studies and phase I clinical trials. This work will advance OncoSynergy’s OS2966 monoclonal antibody drug platform based on its “Targeted Synergy” approach — a transformative strategy allowing single drug inhibition of multiple fundamental cancer growth and treatment resistance mechanisms. OS2966 is being developed for glioblastoma, an aggressive, therapy resistant brain cancer.

For more information, please see the official joint news release.

Translational Research Award at World Federation of Neuro-Oncology Meeting

By | news

OncoSynergy collaborator, Manish K. Aghi, MD, PhD, Associate Professor of Neurosurgery at University of California at San Francisco, was awarded the Young Investigator Award for Basic/Translational Research at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology for work further describing a novel mechanism of antiangiogenic treatment resistance in glioblastoma. This builds upon initial research by OncoSynergy Founder and CEO, W. Shawn Carbonell, MD, PhD and further demonstrates the outstanding potential of OS2966 for the treatment of malignant brain cancers.

Martin Karplus Awarded the 2013 Nobel Prize in Chemistry

By | news

Martin Karplus, a co-inventor of key OncoSynergy technologies, awarded the 2013 Nobel Prize in chemistry. Professor Karplus is the Theodore William Richards Professor of Chemistry Emeritus at Harvard and Visiting Professor at the University of Strasbourg’s Institute of Science and Supramolecular Engineering (CNRS/ Université de Strasbourg).